Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
Recruiting now · Not applicable
Conditions studied: Non-small Cell Lung Cancer Metastatic
In brief
The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.
Key facts
- Study ID
- NCT05889247
- Run by
- Zealand University Hospital
- People needed
- 350
- Starts
- 2023-07-28
- Expected to finish
- 2032-06-01
- Last updated by the study team
- 2026-01-09
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)
- Advanced or locally advanced disease without curative intended treatment options
- Age > 18 years
- Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1
- Measurable disease according to the iRECIST criteria version 1.1.
- Eligible to first line immunotherapy (monotherapy)
- Signed informed consent
You may not qualify if…
- Targetable alterations in EGFR, ALK or ROS-1
- Other active cancers
Where it is running
- Department of Clinical Oncology — Hillerød, Region H, Denmark (enrolling)
- Department of Clinical Oncology and Palliative Care — Næstved, Region Sjælland, Denmark (enrolling)
- Department of Clinical Oncology and Palliative Care — Roskilde, Region Sjælland, Denmark (enrolling)
- Department of Oncology — Aalborg, Denmark
- Department of Oncology — Vejle, Denmark
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.